Company: MDCXW
Filing Date: 2025-11-19
Form Type: S-1
Source: 0001062993-25-016962
Chunk: 2

Company: Medicus Pharma Ltd.
Filing Date: 2025-11-19
Form: S-1
Chunk 2
---
 Ltd. (the "Company"), no par value (the "common shares"), issuable from time to time upon the exercise of up to 2,680,000 warrants to purchase common shares by Armistice Capital Master Fund Ltd. (the "Selling Shareholder" or "Armistice") (the "Private Warrants"). Each Private Warrant is immediately exercisable for one of our common shares at an exercise price of $3.75 and will expire July 15, 2030.

We are not selling any securities under this prospectus and will not receive any of the proceeds from the sale of our common shares by the Selling Shareholder. Information regarding the Selling Shareholder, the number of common shares that may be sold by them and the times and manner in which they may offer and sell the common shares under this prospectus is provided under the sections titled "Selling Shareholder" and "Plan of Distribution" on pages 148 and 150, respectively, of this prospectus. We have not been informed by the Selling Shareholder that they intend to exercise any Private Warrants or sell their common shares covered by this prospectus and do not know when or in what amounts, if any, the Selling Shareholder may offer the common shares for sale. The Selling Shareholder may sell any, all, or none of the common shares offered by this prospectus.

Neither the Company nor any Selling Shareholder has any current arrangements nor entered into any agreements with any underwriters, broker-dealers or selling agents for the sale of the common shares hereby registered.

Our common shares and public warrants, with an exercise price of $4.64 and expiration date of November 15, 2029 (the "Public Warrants") are listed on The Nasdaq Capital Market (the "Nasdaq"), under the symbols "MDCX" and "MDCXW," respectively. The Private Warrants do not trade on any U.S. securities exchange.

The closing prices of our common shares and Public Warrants on Nasdaq on November 18, 2025 were $2.14 and $0.95, respectively.

We are an "emerging growth company" and a "smaller reporting company" under applicable U.S. Securities and Exchange Commission ("SEC") rules and will be eligible for reduced public company disclosure requirements. See"Prospectus Summary-Implications of Being an Emerging Growth Company" and "Prospectus Summary-Implications of Being a Smaller Reporting Company."

Investing in our